Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis

• Published in: Frontiers in immunology Vol. 12; p. 730320
• Main Authors: Zhao, Qing, Zhang, Jianwei, Xu, Lingyi, Yang, Huaxia, Liang, Naixin, Zhang, Li, Zhang, Fengchun, Zhang, Xuan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 27.09.2021
• Subjects: cancer; Drug-Related Side Effects and Adverse Reactions - diagnosis; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - immunology; efficacy; Humans; immune checkpoint inhibitors; Immune Checkpoint Inhibitors - administration & dosage; Immune Checkpoint Inhibitors - adverse effects; immune-related adverse events; Immunology; Incidence; Neoplasms - drug therapy; Neoplasms - immunology; rechallenge; Retreatment; Risk Assessment; Risk Factors; safety; Severity of Illness Index; Treatment Outcome; cancer; immune checkpoint inhibitors; rechallenge; safety; efficacy; immune-related adverse events

Little evidence exists on the safety and efficacy of the rechallenge of immune checkpoint inhibitors (ICIs) after immune-related adverse events (irAEs) in patients with cancer. We searched PubMed, Web of Science, Embase, and Cochrane for articles on ICI rechallenge after irAEs for systemic review an...